The Efficacy and Safety of Bile Acid Binding Agents, Opioid Antagonists, or Rifampin in the Treatment of Cholestasis-Associated Pruritus

Tandon, Puneeta; Rowe, Brian H.; Vandermeer, Ben; Bain, Vincent G.
July 2007
American Journal of Gastroenterology;Jul2007, Vol. 102 Issue 7, p1528
Academic Journal
OBJECTIVES: The objective of this review was to evaluate the efficacy and safety of rifampin, opioid antagonists, or bile acid binding agents in the treatment of cholestasis-related pruritus (CAP) from available randomized controlled trial evidence. METHODS: In addition to a comprehensive gray literature search, the Cochrane Library, MEDLINE, EMBASE, PubMed, and Web of Science were searched. Only full-text RCTs in participants (>75% adult) with CAP on at least one of the three medications were included. The primary outcome was change in pruritus score, recorded as a continuous or dichotomous outcome. Two independent reviewers performed trial selection and quality assessment. RESULTS: From 487 citations, 12 RCTs were included. Rifampin (standardized mean difference [SMD]–1.62, 95% CI –3.05 to –0.18) and opioid antagonists (SMD –0.68, 95% CI –1.19 to –0.17) significantly reduced CAP. The two cholestyramine studies were too heterogeneous to pool. Although cholestyramine ( P= 0.35) and rifampin ( P= 0.96) were not associated with greater side effects compared with placebo, opioid antagonists were (number needed to harm = 2.6, 95% CI 1.4–25). CONCLUSIONS: The available RCTs are small, few in number, and use varying scales for measuring pruritus. Although both opioid antagonists and rifampin demonstrated a reduction in pruritus, there were insufficient data to judge the efficacy of cholestyramine. Opioid antagonists were associated with transient side effects in a significant proportion of patients. A longer well-designed randomized controlled trial is needed to confirm the efficacy of bile acid binding agents and accurately assess adverse events.


Related Articles

  • The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study. Locatelli, Francesco; Spasovski, Goce; Dimkovic, Nada; Wanner, Christoph; Dellanna, Frank; Pontoriero, Giuseppe // Nephrology Dialysis Transplantation;May2014, Vol. 29 Issue 5, p1061 

    Background This study compared the effects of short-term titrated colestilan (a novel non-absorbable, non-calcium, phosphate binder) with placebo, and evaluated the safety and efficacy of colestilan over 1 year compared with sevelamer, in patients with chronic kidney disease (CKD) 5D. Methods...

  • Colesevelam HC1 Improves the Lipid Profile in Type 2 Diabetic Patients with Inadequate Glycemic Control on Sulfonylorea-Based Therapy. Rosenstock, Julio; Fonseca, Vivian; Truitt, Kenneth; Dmuchowski, Carl; Jones, Michael // Diabetes;Jun2007 Supplement 1, Vol. 56, pA537 

    The article focuses on a study on the effect of Colesevelam HCI (COL), is a bile acid sequestrant indicated to reduce low density lipoproteins, in type 2 diabetes mellitus (T2DM) patients with inadequate glycemic control on sulfonylurea (SU)-based therapy. Statistical examinations were conducted...

  • Longitudinal Profiles of 15 Serum Bile Acids in Patients With Intrahepatic Cholestasis of Pregnancy. Tribe, Rachel M.; Dann, Anthony T.; Kenyon, Anna P.; Seed, Paul; Shennan, Andrew H.; Mallet, Anthony // American Journal of Gastroenterology;Mar2010, Vol. 105 Issue 3, p585 

    OBJECTIVES:Increased maternal serum bile acids are implicated in intrahepatic cholestasis of pregnancy. Individual bile acid profiles and their relationship with disease progression, however, remain unknown. The purpose of this prospective study was to determine the temporal changes in bile...

  • Treatment Effect of Rifampicin on Cholestasis. Chen, Jiezhong; Raymond, Kenneth // Internet Journal of Pharmacology;2006, Vol. 4 Issue 2, p4 

    Rifampicin, a semisynthetic antibiotic, has been discovered serendipitously to have beneficial effect on cholestasis. The mechanism, as recently demonstrated, is its induction of pregnane X receptor to regulate the genes involved in bile acids biosynthesis, detoxification and transportation....

  • Pruritus of Cholestasis Treated with Plasma Perfusion. Carey, William D.; Smith, James; Asanuma, Yoshihiro; Malchesky, Paul; Ferguson, D. Roy; Greenstreet, Richard; Nose, Yukihiko // American Journal of Gastroenterology;Oct1981, Vol. 76 Issue 4, p330 

    Patients with uncontrollable pruritus secondary to cholestatic liver disease were subjected to plasma perfusion in an attempt to remove the toxins responsible for this symptom. The improvement in the degree of pruritus was dramatic and surprisingly long-lasting in five of six patients. One...

  • Prescription Opioids and Addiction. Miller, Norman S.; Gold, Mark S. // Psychiatric Annals;Oct2015, Vol. 45 Issue 10, p516 

    Why are opioid medications prescribed in large quantities and high frequency when there is little or no proven efficacy for their therapeutic value? Why are opioids the most commonly prescribed medication in the United States when their adverse consequences continue to grow? Why does the medical...

  • Bile Acids and Collagenous Colitis. DeBaise, J. K.; Thompson, Jon S. // American Journal of Gastroenterology;Jul2000, Vol. 95 Issue 7, p1625 

    Discusses research being done on the role of bile acid binding agents in patients with collagenous colitis. Reference to a study by A. Kilander and colleagues published in a 2000 issue of "Gut" journal; Characteristics of collagenous colitis; Outcome of the bile acid binding treatment...

  • Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Strain, Eric C.; Walsh, Sharon L.; Bigelow, George E. // Psychopharmacology;2002, Vol. 159 Issue 2, p161 

    Rationale: Buprenorphine is an opioid agonist–antagonist used in the treatment of opioid dependence. Naloxone has been combined with buprenorphine to decrease the parenteral abuse potential of buprenorphine. This addition of naloxone may also confer further opioid blockade efficacy....

  • Naltrexone for the Treatment of Alcoholism: Clinical Findings, Mechanisms of Action, and Pharmacogenetics. Ray, Lara A.; Chin, Pauline F.; Miotto, Karen // CNS & Neurological Disorders - Drug Targets;Mar2010, Vol. 9 Issue 1, p13 

    Naltrexone is an opioid receptor antagonist with established efficacy, albeit moderate, for the treatment of alcohol dependence. This manuscript provides a critical review of the literature on naltrexone as a pharmacotherapy for alcoholism by covering the following areas: (a) clinical findings...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics